Cannabinoid receptor 1

Timeframe	Studies on this Protein(%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (1.39)	18.2507
2000's	95 (33.10)	29.6817
2010's	158 (55.05)	24.3611
2020's	30 (10.45)	2.80

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
tacrine	Homo sapiens (human)	Ki	1.0000	1	1
am 251	Homo sapiens (human)	IC50	0.0892	7	7
am 251	Homo sapiens (human)	Ki	0.0167	7	8
cannabinol	Homo sapiens (human)	Ki	0.3728	4	4
econazole	Homo sapiens (human)	IC50	36.2700	1	0
econazole	Homo sapiens (human)	Ki	28.6270	1	0
miconazole	Homo sapiens (human)	IC50	21.0500	1	0
miconazole	Homo sapiens (human)	Ki	16.6140	1	0
nimodipine	Homo sapiens (human)	IC50	1.7360	1	0
nimodipine	Homo sapiens (human)	Ki	1.3710	1	0
palmidrol	Homo sapiens (human)	Ki	5.0000	2	3
mestranol	Homo sapiens (human)	IC50	28.5400	1	0
mestranol	Homo sapiens (human)	Ki	22.5320	1	0
phenothiazine	Homo sapiens (human)	IC50	24.8570	1	0
phenothiazine	Homo sapiens (human)	Ki	19.6240	1	0
indopan	Homo sapiens (human)	Ki	10.0000	1	1
dronabinol	Homo sapiens (human)	IC50	0.0028	1	1
dronabinol	Homo sapiens (human)	Ki	0.0295	18	18
cannabichromene	Homo sapiens (human)	Ki	0.7140	1	1
pravadoline	Homo sapiens (human)	IC50	0.4530	1	1
epigallocatechin gallate	Homo sapiens (human)	Ki	33.6000	2	2
gallocatechol	Homo sapiens (human)	Ki	35.7000	1	1
magnolol	Homo sapiens (human)	Ki	2.5750	2	2
honokiol	Homo sapiens (human)	Ki	2.7432	3	3
(6ar-trans)-isomer of tetrahydrocannabivarin 9	Homo sapiens (human)	IC50	0.0131	1	1
(6ar-trans)-isomer of tetrahydrocannabivarin 9	Homo sapiens (human)	Ki	0.3590	3	3
delta(9)-tetrahydrocannabinolic acid	Homo sapiens (human)	Ki	0.0240	1	1
rimonabant	Homo sapiens (human)	IC50	0.0130	1	1
rimonabant	Homo sapiens (human)	Ki	0.0152	2	2
sr141716	Homo sapiens (human)	IC50	0.0219	31	31
sr141716	Homo sapiens (human)	Ki	0.0447	79	83
cp-55,940	Homo sapiens (human)	IC50	0.0042	13	13
cp-55,940	Homo sapiens (human)	Ki	0.0026	25	27
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol	Homo sapiens (human)	Ki	0.0188	2	2
epicatechin gallate	Homo sapiens (human)	Ki	47.3000	1	1
4-methoxyhonokiol	Homo sapiens (human)	Ki	0.8430	1	4
8-hydroxy-delta(9)-tetrahydrocannabinol	Homo sapiens (human)	Ki	0.0650	1	1
delta-8-tetrahydrocannabinol	Homo sapiens (human)	Ki	0.0438	6	7
cannabidiol	Homo sapiens (human)	Ki	3.1398	4	4
flunarizine	Homo sapiens (human)	IC50	3.0280	1	0
flunarizine	Homo sapiens (human)	Ki	2.3910	1	0
capsaicin	Homo sapiens (human)	Ki	8.9000	3	4
N-(4-chlorophenethyl)-N'-(4-chlorophenyl)urea	Homo sapiens (human)	IC50	0.1622	1	1
orlistat	Homo sapiens (human)	IC50	0.1000	1	1
orlistat	Homo sapiens (human)	Ki	2.5000	1	1
sr 144528	Homo sapiens (human)	IC50	271.3472	2	2
sr 144528	Homo sapiens (human)	Ki	9.8712	12	13
lenabasum	Homo sapiens (human)	Ki	0.0190	2	2
jhw 015	Homo sapiens (human)	Ki	0.8001	6	9
am 281	Homo sapiens (human)	Ki	0.4220	1	1
am 630	Homo sapiens (human)	Ki	3.4151	8	9
anandamide	Homo sapiens (human)	Ki	0.1834	22	23
homo-gamma-linolenylethanolamide	Homo sapiens (human)	Ki	0.3257	2	2
7,10,13,16-docosatetraenylethanolamide	Homo sapiens (human)	Ki	0.0344	1	1
glyceryl 2-arachidonate	Homo sapiens (human)	Ki	0.6055	4	4
arachidonoyl amine	Homo sapiens (human)	Ki	9.6000	1	1
linoleoyl ethanolamide	Homo sapiens (human)	Ki	41.4000	1	1
n-oleoylethanolamine	Homo sapiens (human)	Ki	3.3250	3	4
nabilone	Homo sapiens (human)	Ki	0.0036	2	2
arachidonyl-2-chloroethylamide	Homo sapiens (human)	Ki	0.0053	1	1
l 759633	Homo sapiens (human)	Ki	8.4465	2	2
ly 320135	Homo sapiens (human)	Ki	0.1410	1	1
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	Homo sapiens (human)	IC50	0.0710	7	7
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	Homo sapiens (human)	Ki	0.1907	67	71
cannabigerol	Homo sapiens (human)	IC50	3.3100	1	1
cannabigerol	Homo sapiens (human)	Ki	1.4190	3	3
virodhamine	Homo sapiens (human)	Ki	0.9120	1	1
guineensine	Homo sapiens (human)	Ki	20.0000	1	1
(2E,4E)-N-isobutyl-2,4-dodecadienamide	Homo sapiens (human)	Ki	1.9400	1	1
noladin ether	Homo sapiens (human)	Ki	0.0225	2	2
am 404	Homo sapiens (human)	Ki	1.6300	2	2
jwh-133	Homo sapiens (human)	Ki	0.5557	13	13
CB-13	Homo sapiens (human)	IC50	0.7975	2	2
CB-13	Homo sapiens (human)	Ki	0.0350	2	2
am-411	Homo sapiens (human)	Ki	0.0068	2	2
hu 210	Homo sapiens (human)	Ki	0.0051	6	6
slv 319	Homo sapiens (human)	IC50	0.0185	2	2
slv 319	Homo sapiens (human)	Ki	0.0061	9	9
sr 147778	Homo sapiens (human)	Ki	0.0035	1	1
jte 907	Homo sapiens (human)	Ki	3.1470	2	2
emindole SB	Homo sapiens (human)	Ki	7.0500	1	1
1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1h-indole	Homo sapiens (human)	Ki	2.6585	4	4
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride	Homo sapiens (human)	Ki	1.0000	1	1
amg 3	Homo sapiens (human)	Ki	0.0003	3	4
leucettamine b	Homo sapiens (human)	IC50	10.0000	1	1
cp 945598	Homo sapiens (human)	Ki	0.0010	4	5
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole	Homo sapiens (human)	IC50	0.6310	1	1
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole	Homo sapiens (human)	Ki	0.8294	1	1
am 1241	Homo sapiens (human)	IC50	0.2800	1	1
am 1241	Homo sapiens (human)	Ki	1.7524	8	11
km-233	Homo sapiens (human)	Ki	0.0123	5	5
1-(2,4-dichlorophenyl)-6-methyl-N-(1-piperidinyl)-4H-indeno[1,2-c]pyrazole-3-carboxamide	Homo sapiens (human)	Ki	0.3630	3	3
jwh 018	Homo sapiens (human)	Ki	0.0050	5	6
n-arachidonoyl l-serine	Homo sapiens (human)	Ki	10.0000	1	1
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide	Homo sapiens (human)	IC50	0.0031	18	18
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide	Homo sapiens (human)	Ki	0.0003	1	1
pf 514273	Homo sapiens (human)	Ki	1.6674	5	6
mk-9470	Homo sapiens (human)	IC50	0.0007	2	2
1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea	Homo sapiens (human)	IC50	0.2966	14	14
a-796260	Homo sapiens (human)	IC50	0.3300	2	2
a-796260	Homo sapiens (human)	Ki	0.7558	4	7
cannabidivarin	Homo sapiens (human)	Ki	14.7100	1	1
4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide	Homo sapiens (human)	Ki	0.0110	1	1
omdm 169	Homo sapiens (human)	Ki	10.0000	1	1
a 803467	Homo sapiens (human)	IC50	10.0000	1	1
a-836339	Homo sapiens (human)	Ki	0.2710	2	2
smm-189	Homo sapiens (human)	Ki	3.1943	3	3
n-(adamantan-1-yl)-4-oxo-1-pentyl-6-phenyl-1,4-dihydroquinoline-3-carboxamide	Homo sapiens (human)	Ki	10.0000	2	2
nitd 609	Homo sapiens (human)	IC50	10.0000	1	1
ur-144	Homo sapiens (human)	Ki	0.1473	1	2
misoprostol	Homo sapiens (human)	IC50	0.5230	7	7
am6545	Homo sapiens (human)	Ki	0.0010	1	1
n,n-diallyl-5-methoxytryptamine	Homo sapiens (human)	Ki	10.0000	1	1
s-777469	Homo sapiens (human)	IC50	2.0000	1	1
s-777469	Homo sapiens (human)	Ki	4.4247	3	3
jd5037	Homo sapiens (human)	IC50	0.0005	1	1
((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one)	Homo sapiens (human)	IC50	0.3140	1	1

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
am 251	Homo sapiens (human)	EC50	0.0651	2	3
cannabinol	Homo sapiens (human)	EC50	0.0750	1	1
dronabinol	Homo sapiens (human)	EC50	0.0458	3	3
magnolol	Homo sapiens (human)	EC50	18.3000	1	1
honokiol	Homo sapiens (human)	EC50	10.0000	1	1
rimonabant	Homo sapiens (human)	EC50	0.0101	1	1
rimonabant	Homo sapiens (human)	Kd	0.0025	1	1
sr141716	Homo sapiens (human)	EC50	0.0654	15	16
sr141716	Homo sapiens (human)	Kd	0.0027	8	16
cp-55,940	Homo sapiens (human)	EC50	0.0132	45	50
cp-55,940	Homo sapiens (human)	Kd	0.0016	2	10
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol	Homo sapiens (human)	EC50	0.0006	1	1
3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]-oxomethyl]-N,N-dimethyl-4-(1-pyrrolidinyl)benzenesulfonamide	Homo sapiens (human)	EC50	30.0000	1	1
lenabasum	Homo sapiens (human)	EC50	0.9270	1	1
glyceryl 2-arachidonate	Homo sapiens (human)	EC50	0.0230	1	1
nabilone	Homo sapiens (human)	EC50	0.0040	1	1
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	Homo sapiens (human)	EC50	0.1868	14	14
CB-13	Homo sapiens (human)	EC50	0.0504	3	3
am-411	Homo sapiens (human)	EC50	1.5300	1	1
hu 210	Homo sapiens (human)	EC50	0.0203	2	2
slv 319	Homo sapiens (human)	Kd	0.0001	3	3
1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1h-indole	Homo sapiens (human)	EC50	16.1000	1	1
am 1241	Homo sapiens (human)	EC50	1.0380	1	1
gw 842166x	Homo sapiens (human)	EC50	18.5714	7	7
jwh 018	Homo sapiens (human)	EC50	0.0224	3	5
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide	Homo sapiens (human)	EC50	0.0024	2	2
1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea	Homo sapiens (human)	EC50	0.1279	4	4
a-796260	Homo sapiens (human)	EC50	0.8110	1	1
misoprostol	Homo sapiens (human)	EC50	2.0145	8	8
AKB48	Homo sapiens (human)	EC50	0.0380	1	1
sdb-001	Homo sapiens (human)	EC50	0.0553	3	4

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
cannabinol	Homo sapiens (human)	Log Ki	0.0025	1	1
dronabinol	Homo sapiens (human)	Log Ki	0.0016	1	1
sr141716	Homo sapiens (human)	Kb	0.0007	1	1
sr141716	Homo sapiens (human)	Ke	1.4294	7	7
sr141716	Homo sapiens (human)	Kieq	0.0120	1	1
sr141716	Homo sapiens (human)	Log Ki	0.0011	1	1
cp-55,940	Homo sapiens (human)	Kb	0.0930	1	1
cannabidiol	Homo sapiens (human)	Log Ki	0.0036	1	1
sr 144528	Homo sapiens (human)	Kieq	2.8200	1	1
jhw 015	Homo sapiens (human)	Log Ki	0.0026	1	1
anandamide	Homo sapiens (human)	Log Ki	0.0020	1	1
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	Homo sapiens (human)	Log Ki	0.0003	1	1
cannabigerol	Homo sapiens (human)	K	1.0400	1	1
cp 945598	Homo sapiens (human)	Ke	0.0059	3	3
1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea	Homo sapiens (human)	Kb	0.0542	2	2
n-(adamantan-1-yl)-4-oxo-1-pentyl-6-phenyl-1,4-dihydroquinoline-3-carboxamide	Homo sapiens (human)	Kieq	10.0000	1	1
misoprostol	Homo sapiens (human)	Kb	0.2172	3	3
((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one)	Homo sapiens (human)	Kb	2.2000	1	1

Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 24, Issue:17, 2014

Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 22, Issue:15, 2014

Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
European journal of medicinal chemistry, , Volume: 45, Issue:12, 2010

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity
Bioorganic & medicinal chemistry, , Aug-01, Volume: 17, Issue:15, 2009

Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008

Novel sterically hindered cannabinoid CB1 receptor ligands.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008

Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008

Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.
Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 17, Issue:14, 2007

Phytocannabinoid Pharmacology: Medicinal Properties of
Journal of natural products, , 01-22, Volume: 84, Issue:1, 2021

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
Journal of natural products, , 03-23, Volume: 81, Issue:3, 2018

A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
Journal of medicinal chemistry, , Jun-15, Volume: 43, Issue:12, 2000

Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.
Journal of medicinal chemistry, , Oct-05, Volume: 43, Issue:20, 2000

[no title available]
,

Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
Journal of medicinal chemistry, , May-14, Volume: 52, Issue:9, 2009

[no title available]
,

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.
European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy.
Journal of medicinal chemistry, , 12-14, Volume: 60, Issue:23, 2017

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
ACS medicinal chemistry letters, , Jan-10, Volume: 4, Issue:1, 2013

Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.
Chemistry & biology, , Aug-26, Volume: 18, Issue:8, 2011

Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.
European journal of medicinal chemistry, , Jun-30, Volume: 116, 2016

Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
ACS medicinal chemistry letters, , Jan-10, Volume: 4, Issue:1, 2013

Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.
Chemistry & biology, , Aug-26, Volume: 18, Issue:8, 2011

Phytocannabinoid Pharmacology: Medicinal Properties of
Journal of natural products, , 01-22, Volume: 84, Issue:1, 2021

Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal
Journal of natural products, , 01-24, Volume: 83, Issue:1, 2020

Synthesis of the Major Mammalian Metabolites of THCV.
Journal of natural products, , 07-24, Volume: 83, Issue:7, 2020

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
European journal of medicinal chemistry, , Mar-26, Volume: 93, 2015

Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006

Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation.
Journal of medicinal chemistry, , Apr-07, Volume: 48, Issue:7, 2005

1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
Journal of medicinal chemistry, , Nov-17, Volume: 48, Issue:23, 2005

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.
Chemistry & biology, , Aug-26, Volume: 18, Issue:8, 2011

Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
Journal of natural products, , Jun-26, Volume: 78, Issue:6, 2015

Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
Journal of natural products, , Jun-26, Volume: 78, Issue:6, 2015

Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 19, Issue:6, 2009

Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations.
Bioorganic & medicinal chemistry, , Mar-15, Volume: 17, Issue:6, 2009

Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.
Bioorganic & medicinal chemistry, , Jul-01, Volume: 16, Issue:13, 2008

The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Journal of medicinal chemistry, , Jun-14, Volume: 50, Issue:12, 2007

Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 17, Issue:24, 2007

The Essential Medicinal Chemistry of Cannabidiol (CBD).
Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
Journal of medicinal chemistry, , Jun-15, Volume: 43, Issue:12, 2000

[no title available]
,

Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020

Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
Journal of medicinal chemistry, , May-14, Volume: 52, Issue:9, 2009

Design, synthesis and biological evaluation of GPR55 agonists.
Bioorganic & medicinal chemistry, , 08-15, Volume: 25, Issue:16, 2017

[no title available]
Journal of medicinal chemistry, , 01-13, Volume: 65, Issue:1, 2022

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.
Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008

The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
Journal of medicinal chemistry, , Aug-11, Volume: 48, Issue:16, 2005

The cannabinoid acids, analogs and endogenous counterparts.
Bioorganic & medicinal chemistry, , May-15, Volume: 22, Issue:10, 2014

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Contributions of academic laboratories to the discovery and development of chemical biology tools.
Journal of medicinal chemistry, , Sep-26, Volume: 56, Issue:18, 2013

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010

Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008

A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
Journal of medicinal chemistry, , Jun-15, Volume: 43, Issue:12, 2000

Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.
European journal of medicinal chemistry, , Volume: 44, Issue:2, 2009

Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.
European journal of medicinal chemistry, , Jan-01, Volume: 161, 2019

Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018

[no title available]
European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018

Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
European journal of medicinal chemistry, , Nov-29, Volume: 124, 2016

Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.
Chemistry & biology, , Aug-26, Volume: 18, Issue:8, 2011

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010

New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007

Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor.
Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002

Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor.
Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002

Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
Journal of medicinal chemistry, , 01-12, Volume: 60, Issue:1, 2017

[no title available]
Bioorganic & medicinal chemistry, , 11-01, Volume: 24, Issue:21, 2016

Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
Journal of medicinal chemistry, , Dec-22, Volume: 54, Issue:24, 2011

Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.
Journal of medicinal chemistry, , Jul-28, Volume: 54, Issue:14, 2011

Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
Bioorganic & medicinal chemistry, , Jan-15, Volume: 15, Issue:2, 2007

Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
Journal of medicinal chemistry, , May-14, Volume: 52, Issue:9, 2009

Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
Journal of medicinal chemistry, , Apr-06, Volume: 49, Issue:7, 2006

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 20, Issue:17, 2010

New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.
Journal of medicinal chemistry, , Apr-24, Volume: 51, Issue:8, 2008

Phytocannabinoid Pharmacology: Medicinal Properties of
Journal of natural products, , 01-22, Volume: 84, Issue:1, 2021

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa).
Journal of natural products, , Sep-23, Volume: 74, Issue:9, 2011

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
Journal of medicinal chemistry, , Dec-22, Volume: 54, Issue:24, 2011

Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.
Journal of medicinal chemistry, , Jul-28, Volume: 54, Issue:14, 2011

New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.
Journal of medicinal chemistry, , Dec-25, Volume: 51, Issue:24, 2008

New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 16, Issue:1, 2006

[no title available]
Bioorganic & medicinal chemistry, , 10-01, Volume: 26, Issue:18, 2018

γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 22, Issue:4, 2012

N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.
Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012

Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Journal of medicinal chemistry, , Aug-09, Volume: 50, Issue:16, 2007

Novel adamantyl cannabinoids as CB1 receptor probes.
Journal of medicinal chemistry, , May-23, Volume: 56, Issue:10, 2013

Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations.
Bioorganic & medicinal chemistry, , Mar-15, Volume: 17, Issue:6, 2009

The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Journal of medicinal chemistry, , Jun-14, Volume: 50, Issue:12, 2007

Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB
MedChemComm, , Aug-01, Volume: 8, Issue:8, 2017

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.
Journal of medicinal chemistry, , Jul-28, Volume: 54, Issue:14, 2011

Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009

Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.
European journal of medicinal chemistry, , Volume: 44, Issue:2, 2009

New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007

Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006

The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
Journal of medicinal chemistry, , Aug-11, Volume: 48, Issue:16, 2005

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010

Indoloditerpenes from a marine-derived fungal strain of Dichotomomyces cejpii with antagonistic activity at GPR18 and cannabinoid receptors.
Journal of natural products, , Mar-28, Volume: 77, Issue:3, 2014

[no title available]
MedChemComm, , Nov-01, Volume: 10, Issue:11, 2019

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 21, Issue:8, 2011

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
Journal of medicinal chemistry, , Jan-22, Volume: 52, Issue:2, 2009

Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Journal of medicinal chemistry, , Sep-09, Volume: 53, Issue:17, 2010

Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008

The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Journal of medicinal chemistry, , Jun-14, Volume: 50, Issue:12, 2007

Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 17, Issue:24, 2007

Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.
Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022

Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.
Journal of medicinal chemistry, , 05-24, Volume: 61, Issue:10, 2018

Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.
Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012

Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
Journal of medicinal chemistry, , Mar-22, Volume: 55, Issue:6, 2012

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
Journal of medicinal chemistry, , Jan-22, Volume: 52, Issue:2, 2009

Peripherally restricted CB1 receptor blockers.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013

Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
Bioorganic & medicinal chemistry, , Apr-01, Volume: 21, Issue:7, 2013

Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 25, Issue:1, 2015

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Contributions of academic laboratories to the discovery and development of chemical biology tools.
Journal of medicinal chemistry, , Sep-26, Volume: 56, Issue:18, 2013

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010

Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
Journal of medicinal chemistry, , Jan-22, Volume: 52, Issue:2, 2009

Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008

Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008

Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 19, Issue:6, 2009

Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations.
Bioorganic & medicinal chemistry, , Mar-15, Volume: 17, Issue:6, 2009

Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.
Bioorganic & medicinal chemistry, , Jul-01, Volume: 16, Issue:13, 2008

The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Journal of medicinal chemistry, , Jun-14, Volume: 50, Issue:12, 2007

Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.
Bioorganic & medicinal chemistry letters, , Oct-20, Volume: 13, Issue:20, 2003

Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
European journal of medicinal chemistry, , Jul-23, Volume: 82, 2014

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

[no title available]
ACS medicinal chemistry letters, , Jun-08, Volume: 8, Issue:6, 2017

Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
European journal of medicinal chemistry, , Sep-08, Volume: 137, 2017

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
European journal of medicinal chemistry, , Mar-26, Volume: 93, 2015

Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
Journal of medicinal chemistry, , Aug-13, Volume: 58, Issue:15, 2015

Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009

Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
Journal of medicinal chemistry, , Jan-22, Volume: 52, Issue:2, 2009

Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008

[no title available]
RSC medicinal chemistry, , Feb-23, Volume: 13, Issue:2, 2022

Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists.
Journal of medicinal chemistry, , 05-13, Volume: 64, Issue:9, 2021

Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.
Journal of medicinal chemistry, , 08-25, Volume: 59, Issue:16, 2016

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011

Cannabinomimetic lipid from a marine cyanobacterium.
Journal of natural products, , Oct-28, Volume: 74, Issue:10, 2011

Designing around Structural Alerts in Drug Discovery.
Journal of medicinal chemistry, , 06-25, Volume: 63, Issue:12, 2020

Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.
Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 20, Issue:12, 2010

Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 20, Issue:16, 2010

Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Journal of medicinal chemistry, , May-27, Volume: 53, Issue:10, 2010

Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 20, Issue:4, 2010

Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
Bioorganic & medicinal chemistry letters, , May-01, Volume: 19, Issue:9, 2009

Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 19, Issue:15, 2009

Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 19, Issue:17, 2009

The many roles for fluorine in medicinal chemistry.
Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008

Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008

Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008

Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
Journal of medicinal chemistry, , Jul-26, Volume: 50, Issue:15, 2007

Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Journal of medicinal chemistry, , Dec-28, Volume: 49, Issue:26, 2006

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.
ACS medicinal chemistry letters, , May-10, Volume: 3, Issue:5, 2012

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
Journal of medicinal chemistry, , May-14, Volume: 52, Issue:9, 2009

N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.
Journal of medicinal chemistry, , Apr-28, Volume: 54, Issue:8, 2011

Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
Journal of medicinal chemistry, , Jul-26, Volume: 50, Issue:15, 2007

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.
Bioorganic & medicinal chemistry, , 07-01, Volume: 41, 2021

Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

Allosteric CB
ACS medicinal chemistry letters, , Dec-13, Volume: 9, Issue:12, 2018

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.
Bioorganic & medicinal chemistry, , 12-15, Volume: 25, Issue:24, 2017

[no title available]
Journal of medicinal chemistry, , 02-09, Volume: 60, Issue:3, 2017

Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
Journal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).
Journal of medicinal chemistry, , Sep-25, Volume: 57, Issue:18, 2014

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010

Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
Journal of medicinal chemistry, , Jan-22, Volume: 52, Issue:2, 2009

Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008

Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008

Plant-Based Modulators of Endocannabinoid Signaling.
Journal of natural products, , 03-22, Volume: 82, Issue:3, 2019

Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.
European journal of medicinal chemistry, , Volume: 44, Issue:2, 2009

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.
Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Proceedings of the National Academy of Sciences of the United States of America, , May-15, Volume: 104, Issue:20, 2007

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
Bioorganic & medicinal chemistry, , 03-01, Volume: 33, 2021

Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.
Bioorganic & medicinal chemistry, , Sep-01, Volume: 23, Issue:17, 2015

Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 19, Issue:6, 2009

Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solu
Journal of medicinal chemistry, , Feb-11, Volume: 59, Issue:3, 2016

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011

Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
Journal of medicinal chemistry, , Aug-28, Volume: 51, Issue:16, 2008

Spiroindolones, a potent compound class for the treatment of malaria.
Science (New York, N.Y.), , Sep-03, Volume: 329, Issue:5996, 2010

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.
Bioorganic & medicinal chemistry, , 07-01, Volume: 41, 2021

Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities.
ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020

Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
Journal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016

Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators.
Bioorganic & medicinal chemistry letters, , 09-15, Volume: 26, Issue:18, 2016

Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.
Bioorganic & medicinal chemistry, , May-01, Volume: 23, Issue:9, 2015

Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors.
Journal of medicinal chemistry, , Aug-13, Volume: 58, Issue:15, 2015

Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1).
Journal of medicinal chemistry, , Apr-10, Volume: 57, Issue:7, 2014

Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1).
Journal of medicinal chemistry, , Oct-24, Volume: 56, Issue:20, 2013

Indole-2-carboxamides as allosteric modulators of the cannabinoid CB₁ receptor.
Journal of medicinal chemistry, , Jun-14, Volume: 55, Issue:11, 2012

Peripherally restricted CB1 receptor blockers.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013

Benzo[d]thiazol-2(3H)-ones as new potent selective CB
European journal of medicinal chemistry, , Mar-01, Volume: 165, 2019

Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013

Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 22, Issue:8, 2012

Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility.
MedChemComm, , Dec-01, Volume: 10, Issue:12, 2019

JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.
Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 22, Issue:19, 2012

From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Journal of medicinal chemistry, , 01-14, Volume: 64, Issue:1, 2021

Strategies to develop selective CB
European journal of medicinal chemistry, , Oct-15, Volume: 180, 2019

Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
Journal of medicinal chemistry, , 08-24, Volume: 60, Issue:16, 2017

Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.
Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022

Target	Category	Definition
cannabinoid receptor activity	molecular function	Combining with a cannabinoid to initiate a change in cell activity. Cannabinoids are a class of diverse chemical compounds that include the endocannabinoids and the phytocannabinoids. [GOC:dph, IUPHAR_GPCR:1279, Wikipedia:Cannabinoid]
protein binding	molecular function	Binding to a protein. [GOC:go_curators]
identical protein binding	molecular function	Binding to an identical protein or proteins. [GOC:jl]
G protein-coupled receptor activity	molecular function	Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. [GOC:bf, http://www.iuphar-db.org, Wikipedia:GPCR]

Target	Category	Definition
mitochondrial outer membrane	cellular component	The outer, i.e. cytoplasm-facing, lipid bilayer of the mitochondrial envelope. [GOC:ai]
plasma membrane	cellular component	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363]
actin cytoskeleton	cellular component	The part of the cytoskeleton (the internal framework of a cell) composed of actin and associated proteins. Includes actin cytoskeleton-associated complexes. [GOC:jl, ISBN:0395825172, ISBN:0815316194]
growth cone	cellular component	The migrating motile tip of a growing neuron projection, where actin accumulates, and the actin cytoskeleton is the most dynamic. [GOC:aruk, GOC:bc, ISBN:0815316194, PMID:10082468]
presynaptic membrane	cellular component	A specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane. [GOC:jl, ISBN:0815316194]
membrane raft	cellular component	Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. [PMID:16645198, PMID:20044567]
glutamatergic synapse	cellular component	A synapse that uses glutamate as a neurotransmitter. [GOC:dos]
GABA-ergic synapse	cellular component	A synapse that uses GABA as a neurotransmitter. These synapses are typically inhibitory. [GOC:dos]

Target	Category	Definition
plasma membrane	cellular component	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363]
cytoplasm	cellular component	The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684]

Target	Category	Definition
positive regulation of acute inflammatory response to antigenic stimulus	biological process	Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus. [GOC:add]
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	biological process	A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation or inhibition of a nucleotide cyclase activity and a subsequent change in the concentration of a cyclic nucleotide. [GOC:mah, GOC:signaling, ISBN:0815316194]
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	biological process	A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation or inhibition of adenylyl cyclase activity and a subsequent change in the intracellular concentration of cyclic AMP (cAMP). [GOC:mah, GOC:signaling, ISBN:0815316194]
spermatogenesis	biological process	The developmental process by which male germ line stem cells self renew or give rise to successive cell types resulting in the development of a spermatozoa. [GOC:jid, ISBN:9780878933846, PMID:28073824, PMID:30990821]
axonal fasciculation	biological process	The collection of axons into a bundle of rods, known as a fascicle. [GOC:dgh]
response to nutrient	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nutrient stimulus. [GOC:go_curators]
memory	biological process	The activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. The main stages involved in the formation and retrieval of memory are encoding (processing of received information by acquisition), storage (building a permanent record of received information as a result of consolidation) and retrieval (calling back the stored information and use it in a suitable way to execute a given task). [GOC:curators, ISBN:0582227089]
positive regulation of neuron projection development	biological process	Any process that increases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). [GOC:dph, GOC:tb]
negative regulation of serotonin secretion	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of serotonin. [GOC:ef]
positive regulation of fever generation	biological process	Any process that activates or increases the frequency, rate, or extent of fever generation. [GOC:add]
negative regulation of fatty acid beta-oxidation	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of fatty acid beta-oxidation. [GOC:mah]
regulation of synaptic transmission, GABAergic	biological process	Any process that modulates the frequency, rate or extent of GABAergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter gamma-aminobutyric acid (GABA). [GOC:mah]
response to lipopolysaccharide	biological process	Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. [GOC:add, ISBN:0721601464]
negative regulation of mast cell activation	biological process	Any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell activation. [GOC:mah]
negative regulation of dopamine secretion	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of dopamine. [GOC:sl]
response to nicotine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nicotine stimulus. [GOC:bf, GOC:ef, ISBN:0198506732, ISBN:0582227089]
cannabinoid signaling pathway	biological process	A G protein-coupled receptor signaling pathway initiated by a cannabinoid binding to its receptor on the cell surface, and ending with the regulation of a downstream cellular process, e.g. transcription. Cannabinoids are a class of diverse chemical compounds that include the endocannabinoids and the phytocannabinoids. [GOC:bf, GOC:jc, GOC:signaling, Wikipedia:Cannabinoid]
response to cocaine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cocaine stimulus. Cocaine is a crystalline alkaloid obtained from the leaves of the coca plant. [GOC:ef, GOC:jl]
glucose homeostasis	biological process	Any process involved in the maintenance of an internal steady state of glucose within an organism or cell. [GOC:go_curators]
positive regulation of apoptotic process	biological process	Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis]
response to ethanol	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus. [GOC:go_curators]
negative regulation of action potential	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels. [GOC:go_curators]
negative regulation of blood pressure	biological process	Any process in which the force of blood traveling through the circulatory system is decreased. [GOC:go_curators, GOC:mtg_cardio]
positive regulation of blood pressure	biological process	Any process in which the force of blood traveling through the circulatory system is increased. [GOC:go_curators, GOC:mtg_cardio]
regulation of insulin secretion	biological process	Any process that modulates the frequency, rate or extent of the regulated release of insulin. [GOC:ai]
regulation of synaptic transmission, glutamatergic	biological process	Any process that modulates the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate. [GOC:ai]
maternal process involved in female pregnancy	biological process	A reproductive process occurring in the mother that allows an embryo or fetus to develop within it. [GOC:dph]
regulation of feeding behavior	biological process	Any process that modulates the rate, frequency or extent of the behavior associated with the intake of food. [GOC:BHF, GOC:dph, GOC:tb]
regulation of penile erection	biological process	Any process that modulates the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow. [GOC:add, GOC:dph, GOC:tb]
retrograde trans-synaptic signaling by endocannabinoid	biological process	Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by an endocannabinoid ligand. [GOC:dos]
regulation of presynaptic cytosolic calcium ion concentration	biological process	Any process that regulates the concentration of calcium in the presynaptic cytosol. [GOC:dos]
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	biological process	Cell-cell signaling between presynapse and postsynapse, via the release and reception of endocannabinoid ligands, that modulates the synaptic transmission properties of the synapse. [GOC:dos, PMID:21531987]
adenylate cyclase-activating G protein-coupled receptor signaling pathway	biological process	A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of adenylyl cyclase activity which results in an increase in the intracellular concentration of cyclic AMP (cAMP). This pathway is negatively regulated by phosphodiesterase, which cleaves cAMP and terminates the signaling. [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194]
regulation of metabolic process	biological process	Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. [GOC:go_curators]

Synonyms

Research

Bioassay Publications (287)

Compounds (98)

Drugs with Inhibition Measurements

Drugs with Activation Measurements

Drugs with Other Measurements

Enables

Located In

Active In

Involved In